157 related articles for article (PubMed ID: 26640147)
41. TLE1 is a robust diagnostic biomarker for synovial sarcomas and correlates with t(X;18): analysis of 319 cases.
Knösel T; Heretsch S; Altendorf-Hofmann A; Richter P; Katenkamp K; Katenkamp D; Berndt A; Petersen I
Eur J Cancer; 2010 Apr; 46(6):1170-6. PubMed ID: 20189377
[TBL] [Abstract][Full Text] [Related]
42. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma.
Thomas DG; Giordano TJ; Sanders D; Biermann S; Sondak VK; Trent JC; Yu D; Pollock RE; Baker L
Cancer; 2005 Feb; 103(4):830-8. PubMed ID: 15641030
[TBL] [Abstract][Full Text] [Related]
43. Thyroid synovial sarcoma: a case report.
Ghafouri A; Anbara T; Mir A; Lashkari M; Nazari M
Acta Med Iran; 2013; 51(1):69-72. PubMed ID: 23456589
[TBL] [Abstract][Full Text] [Related]
44. Synovial sarcoma: defining features and diagnostic evolution.
Thway K; Fisher C
Ann Diagn Pathol; 2014 Dec; 18(6):369-80. PubMed ID: 25438927
[TBL] [Abstract][Full Text] [Related]
45. LGR5 Is a Gastric Cancer Stem Cell Marker Associated with Stemness and the EMT Signature Genes NANOG, NANOGP8, PRRX1, TWIST1, and BMI1.
Wang B; Chen Q; Cao Y; Ma X; Yin C; Jia Y; Zang A; Fan W
PLoS One; 2016; 11(12):e0168904. PubMed ID: 28033430
[TBL] [Abstract][Full Text] [Related]
46. The interaction of hepatoma-derived growth factor and β-catenin promotes tumorigenesis of synovial sarcoma.
Tang J; Shi H; Li H; Zhen T; Dong Y; Zhang F; Yang Y; Han A
Tumour Biol; 2016 Aug; 37(8):10287-301. PubMed ID: 26842923
[TBL] [Abstract][Full Text] [Related]
47. A conditional mouse model of synovial sarcoma: insights into a myogenic origin.
Haldar M; Hancock JD; Coffin CM; Lessnick SL; Capecchi MR
Cancer Cell; 2007 Apr; 11(4):375-88. PubMed ID: 17418413
[TBL] [Abstract][Full Text] [Related]
48. Establishment of a synovial sarcoma model in athymic nude mice.
Steinstraesser L; Hauk J; Jacobsen F; Stricker I; Steinau HU; Al-Benna S
In Vivo; 2011; 25(2):165-9. PubMed ID: 21471530
[TBL] [Abstract][Full Text] [Related]
49. TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies.
Terry J; Saito T; Subramanian S; Ruttan C; Antonescu CR; Goldblum JR; Downs-Kelly E; Corless CL; Rubin BP; van de Rijn M; Ladanyi M; Nielsen TO
Am J Surg Pathol; 2007 Feb; 31(2):240-6. PubMed ID: 17255769
[TBL] [Abstract][Full Text] [Related]
50. Extent, relationship and prognostic significance of apoptosis and cell proliferation in synovial sarcoma.
Sun B; Sun Y; Wang J; Zhao X; Wang X; Hao X
Eur J Cancer Prev; 2006 Jun; 15(3):258-65. PubMed ID: 16679870
[TBL] [Abstract][Full Text] [Related]
51. Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology.
Nielsen TO; Hsu FD; O'Connell JX; Gilks CB; Sorensen PH; Linn S; West RB; Liu CL; Botstein D; Brown PO; van de Rijn M
Am J Pathol; 2003 Oct; 163(4):1449-56. PubMed ID: 14507652
[TBL] [Abstract][Full Text] [Related]
52. Modeling synovial sarcoma: timing is everything.
Davis SR; Meltzer PS
Cancer Cell; 2007 Apr; 11(4):305-7. PubMed ID: 17418406
[TBL] [Abstract][Full Text] [Related]
53. SYT-SSX1 and SYT-SSX2 interfere with repression of E-cadherin by snail and slug: a potential mechanism for aberrant mesenchymal to epithelial transition in human synovial sarcoma.
Saito T; Nagai M; Ladanyi M
Cancer Res; 2006 Jul; 66(14):6919-27. PubMed ID: 16849535
[TBL] [Abstract][Full Text] [Related]
54. Prognostic implication of SYT-SSX fusion type in synovial sarcoma: a multi-institutional retrospective analysis in Japan.
Takenaka S; Ueda T; Naka N; Araki N; Hashimoto N; Myoui A; Ozaki T; Nakayama T; Toguchida J; Tanaka K; Iwamoto Y; Matsumine A; Uchida A; Ieguchi M; Kaya M; Wada T; Baba I; Kudawara I; Aoki Y; Yoshikawa H
Oncol Rep; 2008 Feb; 19(2):467-76. PubMed ID: 18202796
[TBL] [Abstract][Full Text] [Related]
55. Underlying Ossification Phenotype in a Murine Model of Metastatic Synovial Sarcoma.
Kirkham M; Kalivas A; Fatema K; Luelling S; Dubansky BH; Dubansky B; Jones KB; Barrott JJ
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32290096
[TBL] [Abstract][Full Text] [Related]
56. Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10.
Fukukawa C; Hanaoka H; Nagayama S; Tsunoda T; Toguchida J; Endo K; Nakamura Y; Katagiri T
Cancer Sci; 2008 Feb; 99(2):432-40. PubMed ID: 18271942
[TBL] [Abstract][Full Text] [Related]
57. Geometrical analysis identified morphological features of hydrogel-induced cancer stem cells in synovial sarcoma model cells.
Ferdous Z; Clément JE; Gong JP; Tanaka S; Komatsuzaki T; Tsuda M
Biochem Biophys Res Commun; 2023 Jan; 642():41-49. PubMed ID: 36549099
[TBL] [Abstract][Full Text] [Related]
58. SOX2 Expression and Transcriptional Activity Identifies a Subpopulation of Cancer Stem Cells in Sarcoma with Prognostic Implications.
Menendez ST; Rey V; Martinez-Cruzado L; Gonzalez MV; Morales-Molina A; Santos L; Blanco V; Alvarez C; Estupiñan O; Allonca E; Rodrigo JP; García-Castro J; Garcia-Pedrero JM; Rodriguez R
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32295077
[TBL] [Abstract][Full Text] [Related]
59. Targeting sarcoma tumor-initiating cells through differentiation therapy.
Han D; Rodriguez-Bravo V; Charytonowicz E; Demicco E; Domingo-Domenech J; Maki RG; Cordon-Cardo C
Stem Cell Res; 2017 May; 21():117-123. PubMed ID: 28433655
[TBL] [Abstract][Full Text] [Related]
60. CXCR4 Expression as a Prognostic Biomarker in Soft Tissue Sarcomas.
Virgili AC; Salazar J; Gallardo A; López-Pousa A; Terés R; Bagué S; Orellana R; Fumagalli C; Mangues R; Alba-Castellón L; Unzueta U; Casanova I; Sebio A
Diagnostics (Basel); 2024 Jun; 14(11):. PubMed ID: 38893721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
